电子邮件： liangxuewu0714@simm.ac.cn
通信地址： 上海市浦东新区祖冲之路555号
邮政编码： 201203
研究领域
1. 基于新靶标新机制的创新药物研究
2. 基于天然产物改造的创新药物研究
3. 基于双靶标协同调控机制的创新药物研究
招生信息
药学方向研究生
招生专业
招生方向
教育背景
学历
研究生学历
学位
博士研究生
工作经历
工作简历
专利与奖励
奖励信息
专利成果
出版信息
发表论文
1.Weiwei Hu , Jiaping Ni , Shufang Zheng , Xiaohui Wei , Dongqing Zhai , Jinglin Qi , Xinqi Ye , Mingyin Lu , Hanrui Bian , Jintong Li , Yumeng Shen , Jingwei Jiang , Weijun Zhao , Xueqing Shao , Shihao Xu , Xuewu Liang* , Hong Liu* , Yong Yang*. Identification of a Small-molecule Targeting PLAGL2 DNA-binding Domain Inhibits Extracellular Matrix Formation and Enhances Lenvatinib Sensitivity in Hepatocellular Carcinoma. Acta Pharmaceutica Sinica B. 2026, 16(3), 1489–1509.
2.Xuewu Liang, Yue Huang, Hairu Ren, Qi Liu, Liang Chen, Jiayan Zhao, Xiangqian Gao, Jian Lu, Cai-Guang Yang, Hong Liu. Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity. Journal of Medicinal Chemistry 2025, 68, 2742–2763.
3.Rui Shi, Renwen Liang, Fang Wang, Lueli Wang, Wuyi Zidai, Jie Zhang, Luo Min, Xiaohua Du, Shibo Sun, Chuang Xiao, Chaozhong Li, Xuewu Liang*, Alex F. Chen*, Weimin Yang*. Identification and Experimental Validation of PYCARD as a Crucial PANoptosis-related Gene for Immune Response and Inflammation in COPD. Apoptosis. 2024, 29, 2091-2107.
4.Abdusaid Saidahmatov, Jianan Li, Shihao Xu, Xiaobei Hu, Xiangqian Gao, Weijuan Kan, Lixin Gao, Cong Li,Yuqiang Shi, Li Sheng, Peipei Wang, Yubo Zhou, Xuewu Liang*, Jia Li*, Hong Liu*. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. Journal of Medicinal Chemistry 2024, 67, 17, 15220–15245.
5.Xuewu Liang, Haolan Yu, Renwen Liang, Zhuanghui Feng, Abdusaid Saidahmatov, Chenxia Sun, Hairu Ren, Xiaohui Wei, Jiayan Zhao, Chenghua Yang, Hong Liu. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-Dihydrothiazolo[4,5-d]Pyrimidin-7(6H)-One" Scaffold for the Treatment of B Cell Lymphoma. Journal of Medicinal Chemistry. 2024, 67, 2884-2906.
6. Xuewu Liang, Hairu Ren, Fengyang Han, Renwen Liang, Jiayan Zhao, Hong Liu. The New Direction of Drug Development: Degradation of Undruggable Targets Through Targeting Chimera Technology. Medicinal Research Reviews. 2024, 44, 632–685.
7.Qi Liu, Xuyi Liu, Yazhou Li, Yu Zhou, Linxiang Zhao, Xuewu Liang,* Hong Liu.* Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity. Chemistry—A European Journal. 2023, e202301553.
8.Feifei Fang, Yang Dai, Hao Wang, Yinchun Ji, Xuewu Liang, Xia Peng, Jiyuan Li, Yangrong Zhao, Chunpu Li, Danyi Wang, Yazhou Li, Dong Zhang, Dan Zhang, Meiyu Geng, Hong Liu, Jing Ai, Yu Zhou. Structure-based Drug Discovery of Novel Fused-pyrazolone Carboxamide Derivatives as Potent and Selective AXL Inhibitors. Acta Pharmaceutica Sinica B. 2023, 13(12), 4918–4933.
9.Xuewu Liang, Yongle Xie, Xuyi Liu, Hui Xu, Hairu Ren, Shuai Tang, Qi Liu, Min Huang, Xueqing Shao, Chunpu Li, Yu Zhou, Meiyu Geng, Zuoquan Xie, Hong Liu. Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis. Journal of Medicinal Chemistry. 2022, 65, 11949−11969.
10.Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, Hong Liu. Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. Journal of Medicinal Chemistry. 2022, 65, 1243–1264.
11. Xuewu Liang, Chenxia Sun, Chunpu Li, Haolan Yu, Xiaohui Wei, Xuyi Liu, Wei Bao, Yuqiang Shi, Xiaochen Sun, Mirzadavlat Khamrakulov, Chenghua Yang, Hong Liu. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma. Journal of Medicinal Chemistry. 2021, 64, 9217−9237.
12.Xuewu Liang, YiChun Cao, Chunpu Li, Haolan Yu, Chenghua Yang, Hong Liu. MALT1 as a Promising Target to Treat Lymphoma and Other Diseases Related to MALT1 Anomalies. Medicinal Research Reviews. 2021, 41, 2388–2422.
13. Xiaohui Wei,# Xuewu Liang,# Yazhou Li, Qi Liu, Xuyi Liu, Yu Zhou, Hong Liu. I2-induced Cascade Cyclization and Dearomatization of Indoles for the Highly Efficient Synthesis of Iodinated and Vinylic Spiroindolenines. Green Chemistry. 2021, 23, 9165-9171.
14.Xuewu Liang, Hong Liu, Yingjie Zhang. Novel-targeted Therapy for Hematological Malignancies with JAK and HDAC Dual Inhibitors. Future Medicinal Chemistry. 2019, DOI: 10.4155/fmc-2019-0168.
15. Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu, Yingjie Zhang. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry. 2019, 62(8), 3898-3923.
出版物
（1） 《高等药物化学——药物发现与结构优化策略》, 科学出版社, 2025-08, 编委
（2） 《新编麻醉药理学》, 人民卫生出版社, 2025-08, 编委
（3） 《药物化学与药物研发案例》, 清华大学出版社, 2024-11, 编委